市場調查報告書
商品編碼
1634193
全球神經外科市場 - 2025 - 2033Global Neurosurgery Market - 2025 - 2033 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2024年,全球神經外科市場規模達49.4億美元,預計2033年將達75.4億美元,2025-2033年預測期間複合年成長率為4.5%。
神經外科是一個專門的醫學領域,涉及神經系統問題的診斷、治療和復健。這包括大腦、脊髓、周邊神經和腦血管系統。神經外科醫師接受過培訓,可以進行各種外科手術來治療外傷、腫瘤、先天畸形和退化性疾病等疾病。該領域包括手術和非手術管理程序,允許採用更全面的患者護理方法,包括預防、診斷和復健。
神經外科作為一門活躍的專業,隨著技術和手術的突破而不斷變化。機器人輔助手術和術中影像等創新提高了手術精確度和病患治療效果。此外,對神經系統疾病的更好理解正在推動新治療方法的研究,這可能使神經外科醫生能夠治療更複雜的神經系統疾病。最終,神經外科是現代醫學的重要組成部分,因為它解決了世界各地人們所經歷的一些最困難的健康問題。
驅動程式和限制
技術進步
技術進步預計將成為全球神經外科市場成長的重要因素。隨著神經外科的發展,外科手術和設備的進步提高了各種神經系統疾病治療的精確度和療效。人工智慧 (AI) 和機器學習 (ML) 等現代技術的融合正在改變診斷和治療程序,從而為患者提供更準確的評估和個人化治療程序。
例如,2024 年3 月,中國科學院(CAS) 旗下香港研究中心推出了一款新的人工智慧(AI) 工具CARES Copilot 1.0,以協助複雜的腦部手術,即使醫療保健產業面臨複雜的腦部手術。 CARES Copilot 1.0人工智慧模型幫助神經外科醫生提供更有效率的臨床診斷,並在充分參考的基礎上做出更好的醫療判斷。
微創外科手術是神經外科領域的另一項重大成就。這些方法使用的切口比典型的開放性手術更小,可以減少患者創傷、加快恢復速度並減少併發症。神經內視鏡工具和機器人輔助手術系統等專用設備的引進,使得困難的手術能夠更準確、更有效率地進行。因此,患者可以受益於更快的恢復時間和更好的結果,從而增加了對這些革命性手術方法的需求。
此外,神經外科市場正在經歷研發的增加,重點是開發可提高手術能力的下一代設備。製造商正在逐步投資開發新的電動工具,這些工具結合了即時成像和人工智慧功能,為外科醫生在手術過程中提供了無與倫比的精確度。這種對技術創新的重視不僅提高了營運效率,而且符合客製化醫療日益成長的趨勢,即根據患者獨特的醫療狀況,根據患者的個人需求量身定做治療方案。
例如,2024 年 4 月,Insightec 宣佈在歐洲推出其下一代神經外科平台。 Exablate Prime 也獲得了 CE 許可。這款革命性的設備極大地增強了現有的 Exablate Neuro 平台,該平台使用磁振造影 (MRI) 引導的聚焦超音波技術。 Exablate Prime 旨在治療特發性震顫和帕金森氏症等藥物難治性運動障礙,允許將無切口神經外科手術作為門診手術,為患者提供一種非侵入性治療替代方案,最大限度地縮短康復時間和住院時間。
神經外科設備成本高
神經外科設備的高成本等因素預計將阻礙全球神經外科市場。神經外科設備的高成本預計將嚴重阻礙全球神經外科產業的成長。隨著對改進手術技術的需求不斷成長,複雜設備的成本也不斷增加。對於許多醫療機構來說,購買和維護先進技術的成本可能是一個重大挑戰,特別是在經濟有限的地區。由於持續需要投資指導員工有效地使用這些新儀器,這種情況變得更加複雜,這又增加了醫院預算的成本。
例如,根據美國國立衛生研究院的數據,深部腦部刺激裝置的成本從 10,000 美元到 14,000 美元不等。深部腦部刺激的手術和設備總成本(每位患者)從 27,497 美元到 35,531 美元不等。
The global neurosurgery market reached US$ 4.94 billion in 2024 and is expected to reach US$ 7.54 billion by 2033, growing at a CAGR of 4.5% during the forecast period 2025-2033.
Neurosurgery is a specialized field of medicine concerned with the diagnosis, treatment, and rehabilitation of neurological concerns. This encompasses the brain, spinal cord, peripheral nerves, and cerebrovascular system. Neurosurgeons are trained to undertake a wide range of surgical procedures to treat disorders such as traumatic injuries, tumors, congenital abnormalities, and degenerative diseases. The field comprises both operative and non-operative management procedures, allowing for a more comprehensive approach to patient care, including prevention, diagnosis, and rehabilitation.
Neurosurgery, as an active specialization, constantly changes in response to technological and surgical breakthroughs. Innovations like robotic-assisted surgery and intraoperative imaging improve procedure precision and patient outcomes. Furthermore, a better understanding of neurological diseases is driving research into new treatment methods, which may allow neurosurgeons to manage more complex neurological conditions. Ultimately, neurosurgery is an important part of modern medicine since it addresses some of the most difficult health concerns that people experience around the world.
Market Dynamics: Drivers & Restraints
Technological advancements
The Technological Advancements are expected to be a significant factor in the growth of the global neurosurgery market. As neurosurgery evolves, advances in surgical procedures and equipment improve the precision and efficacy of treatments for a variety of neurological diseases. The integration of modern technology such as artificial intelligence (AI) and machine learning (ML) is transforming diagnostic and therapeutic procedures, allowing for more accurate assessments and personalized treatment procedures for patients.
For instance, in March 2024, A Hong Kong-based research center under the Chinese Academy of Sciences (CAS) launched a new artificial intelligence (AI) tool CARES Copilot 1.0 to assist in complex brain surgery, even as the healthcare industry deals with an inadequate number of specialized databases for this procedure. CARES Copilot 1.0 AI model to help neurosurgeons provide more efficient clinical diagnoses and make better medical judgments based on sufficient references.
Minimally invasive surgical procedures are an additional significant accomplishment in neurosurgery. These approaches, which use smaller incisions than typical open surgeries, result in less patient trauma, faster recovery, and fewer complications. The introduction of specialized devices, such as neuroendoscopic tools and robotic-assisted surgical systems, has enabled difficult procedures to be performed more accurately and efficiently. As a result, patients benefit from faster recovery times and better outcomes, increasing demand for these revolutionary surgical approaches.
Furthermore, the neurosurgery market is experiencing a rise in R&D focused on developing next-generation equipment that improves surgical capabilities. Manufacturers are progressively investing in the development of new power tools that incorporate real-time imaging and AI capabilities, giving surgeons unparalleled levels of precision during procedures. This emphasis on technology innovation not only enhances operational efficiency but also corresponds with the growing trend toward customized medicine, in which therapies are tailored to the individual needs of patients based on their distinct medical profiles.
For instance, in April 2024, Insightec announced the launch of its next-generation neurosurgical platform in Europe. Exablate Prime also received CE clearance. This revolutionary device substantially enhances the existing Exablate Neuro platform, which uses magnetic resonance imaging (MRI)-guided focused ultrasound technology. Exablate Prime, designed to treat medication-refractory movement disorders such as essential tremor and Parkinson's disease, allows for incision-less neurosurgery as an outpatient operation, allowing patients a non-invasive treatment alternative that minimizes recovery time and hospital stays.
High costs of neurosurgery equipment
Factors such as high costs of neurosurgery equipment are expected to hamper the global neurosurgery market. The high costs of neurosurgical devices are expected to severely impede the growth of the global neurosurgery industry. As the need for improved surgical technology grows, so does the cost of the complex equipment. The cost of buying and maintaining advanced technology can be a significant challenge for many healthcare facilities, especially in areas with limited economies. This scenario is further complicated by the ongoing need to invest in instructing staff to utilize these new instruments efficiently, which adds another layer of cost to hospitals' budgets.
For instance, according to the National Institute of Health, the cost of a deep brain stimulation device ranges from $10,000 to $14,000. The total operative and device costs (per patient) range from $27,497 to $35,531 for deep brain stimulation.
The global neurosurgery market is segmented based on product, application, age group, end-user, and region.
Neuro interventional devices segment is expected to dominate the global neurosurgery market share
The radiofrequency coils segment is anticipated to dominate the global neurosurgery market owing to its technological advancements, recent launches and approvals, and increase in the number of neurological disorders. One of the primary benefits of neuro-interventional devices is their capacity to facilitate minimally invasive operations, which are associated with shorter recovery times, fewer postoperative problems, and less trauma for patients when compared to traditional open surgeries. These devices comprise several instruments including stents, embolic coils, and neurothrombectomy devices, all of which are intended to treat problems such as aneurysms and ischemic strokes using endovascular techniques. As healthcare practitioners become more aware of the benefits of these procedures, the demand for neuro-interventional devices is projected to increase significantly.
Furthermore, technological improvements have resulted in the creation of increasingly complex neuro-interventional devices that improve procedural accuracy and safety. Neurosurgeons may now execute difficult operations with better precision because of developments in robotics and imaging technology. This technical advancement not only improves surgical outcomes but also broadens the types of conditions that can be treated with these devices. As a result, healthcare institutions are more likely to invest in neuro-interventional technology, strengthening their position as an important segment of the neurosurgery market.
For instance, in February 2024, Royal Philips launched the new Azurion neuro biplane interventional system, which significantly improves its image-guided therapeutic system. The technology is intended to streamline neurovascular operations, allowing care teams to make faster judgments, treat more patients, and achieve better results. It has superior 2D and 3D imaging capabilities, as well as adjustable X-ray detector positioning. The device allows neuro-interventionists to carry out procedures more efficiently, perhaps increasing patient outcomes. This improves the experience for both staff and patients while also helping to reduce the cost of care. The Azurion neuro biplane system incorporates Philips' ClarityIQ low-dose imaging technology, neuro-specific tools, and services, resulting in a fully integrated solution for smooth procedural workflows, precise diagnosis, and treatment.
Moreover, in June 2024, MicroVention, a subsidiary of Terumo Corporation, launched its LVIS EVO Intraluminal Support Device in the United States. It is specifically intended for the treatment of wide-neck intracranial aneurysms. This novel device is now commercially accessible and represents a substantial improvement in neurovascular therapies.
North America is expected to hold a significant position in the global neurosurgery market share
North America will likely account for a significant share of the global neurosurgery market, owing to its advanced healthcare infrastructure, a high prevalence of neurological disorders, technological advancements, and recent launches and approvals. One of the key drivers of the North America neurosurgery market is a strong healthcare system that allows for better surgical methods and technology. The United States, in particular, has established itself as a leader in medical technology development, with a number of major companies functioning in the neurosurgical field. These corporations constantly invest in R&D to develop new devices and improve existing ones. The existence of large manufacturers, as well as a robust regulatory environment, make it easier to introduce advanced neurosurgical devices, which enhances patient care.
For instance, in March 2024, Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced that it had launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States. This launch expands upon the company's prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy.
Moreover, in April 2024, Expanse ICE announced that the ICE Aspiration System had received 510(k) clearance from the U.S. Food and Drug Administration. The ICE System is specifically designed to address the complex challenges associated with peripheral thrombectomies. Blood clots are the third most common vascular disease.
Asia Pacific is growing at the fastest pace in the global neurosurgery market
The Asia Pacific region is emerging as the fastest-growing market for neurosurgery, owing to a combination of demographic trends, increased healthcare investment, recent launches, and a rising number of neurological disorders. One of the most significant technical advances in the APAC neurosurgery market is the incorporation of robotics and minimally invasive techniques. These innovations enable more accurate surgical procedures, lowering the trauma associated with traditional open surgeries. Additionally, high-definition imaging tools have transformed preoperative planning and intraoperative guidance in neurosurgery. Advanced imaging modalities, such as MRI and CT scans, provide extensive information about brain anatomy, allowing surgeons to see complicated structures before and during surgery. This ability improves surgical precision, lowers the risk of complications, and, eventually, leads to improved patient results. Furthermore, the introduction of artificial intelligence (AI) and machine learning into diagnostic and surgical technologies improves the efficiency and effectiveness of neurosurgical treatments.
For instance, in February 2024, Indian medical imaging AI company InMed AI launched a new AI-powered tool for screening traumatic brain injuries (TBI). The Neuroshield CT TBI is a decision support tool for detecting and quantifying intracranial hemorrhage, fracture, and midline shift. Utilizing AI, it automatically processes brain CT images and alerts clinicians of critical findings.
The major global players in the global neurosurgery market include Medtronic, Abbott, Boston Scientific Corporation, Elekta, Brainlab AG, B. Braun SE, MicroVention, Inc., Aleva Neurotherapeutics, Integra LifeSciences, and Stryker among others.
Emerging Players
Neurotech Innovations, Cadence Neuroscience, and Synaptive Medical among others
The global neurosurgery market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
LIST NOT EXHAUSTIVE